Immunomodulating action of neuropeptides in in vitro systems
Karpov RS, Beĭko VA, Vasil'chenko EM · 1987 · Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
Dalargin increased or decreased mitogen-driven proliferation depending on the initial cellular response, and inhibited leukocyte migration at 0.1 µg/mL.
Human-serum observational component from 55 patients, plus separate in-vitro lymphocyte and leukocyte assays. The 55 is not a Dalargin-treated cohort.
Dose, route and schedule
Dalargin 0.1 µg/mL in the leukocyte-migration assay. A complete concentration/time protocol for the proliferation assay is not given.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Lymphocyte proliferation | Increase or decrease depended on baseline responsiveness to phytohemagglutinin | Bidirectional culture response; not a uniform immune stimulant |
| Leukocyte migration | Inhibition reported with Dalargin 0.1 µg/mL | Culture assay; numerical migration change unavailable |
| Serum correlation component | Serum from 55 patients; endogenous leu-enkephalin inversely correlated with mitogen responsiveness | Observational association, not 55 patients receiving Dalargin |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- In-vitro donor counts, response magnitudes and exposure duration unavailable in the abstract.
- Observational serum results and drug-exposure experiments are different components.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Karpov RS, Beĭko VA, Vasil'chenko EM. Immunomodulating action of neuropeptides in in vitro systems Zh Mikrobiol Epidemiol Immunobiol. 1987;(3):65-68. PMID 3591128 1987.
Molekul research summary: https://molekul.io/research/dalargin-bidirectional-immunity-1987. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry